DHT Blockers and the Risk of Prostate Cancer
Wednesday, July 13th, 2011
Avodart (dutasteride) and Propecia (finasteride) have recently been in the news for the report of some studies regarding their role in increased or decreased risk of prostate cancer. Avodart and Propecia are both 5-alpha reductase inhibitors (5-ARI), which help prevent production of DHT (dihydrotestosterone). This class of medications is indicated for the treatment of benign prostate (BPH) hypertrophy. These DHT blockers also help with the prevention of male patterned hair loss and have been recommended and prescribed for hair loss treatment, for many years.
On one hand, several studies have indicated that DHT blockers could decrease the rate of prostate cancer. On the other hand, there are some studies that indicate they may increase the incidence of high-grade prostate cancers. Those studies performed on both finasteride (7 years study) and dutasteride (4 years study). It has been concluded that the patients who take DHT blockers should have prior knowledge of whether they have a lower risk of prostate cancer. However, if the patient gets prostate cancer it might be in a category which is more advanced.
Doctors should be aware DHT blockers can decrease the levels of PSA artificially, so a small increase in PSA levels might reflect a higher activity of prostate tissue in comparison to patients who are not on DHT blockers. Overall, it is good practice to make sure all patients age 50 and older have a baseline PSA reading before they get started on finasteride. This will determine their PSA levels before they begin taking medications, and the doctor will be able to monitor changes in PSA with greater precision.


Parsa Mohebi, M.D. _______________________________
US Hair Restoration _______________________________
Visit Our Facebook Page